Kornitzer Capital Management Inc. KS Has $17.55 Million Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Kornitzer Capital Management Inc. KS lifted its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 5.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 474,734 shares of the biopharmaceutical company's stock after buying an additional 23,210 shares during the period. Kornitzer Capital Management Inc. KS owned about 0.36% of Halozyme Therapeutics worth $17,546,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the stock. Knights of Columbus Asset Advisors LLC lifted its stake in shares of Halozyme Therapeutics by 99.2% in the fourth quarter. Knights of Columbus Asset Advisors LLC now owns 185,845 shares of the biopharmaceutical company's stock valued at $6,869,000 after buying an additional 92,552 shares during the period. Federated Hermes Inc. lifted its stake in shares of Halozyme Therapeutics by 176.0% in the fourth quarter. Federated Hermes Inc. now owns 459,369 shares of the biopharmaceutical company's stock valued at $16,978,000 after buying an additional 292,926 shares during the period. Livforsakringsbolaget Skandia Omsesidigt bought a new stake in shares of Halozyme Therapeutics in the fourth quarter valued at about $196,000. Cornercap Investment Counsel Inc. lifted its stake in Halozyme Therapeutics by 130.9% during the fourth quarter. Cornercap Investment Counsel Inc. now owns 28,085 shares of the biopharmaceutical company's stock worth $1,038,000 after purchasing an additional 15,924 shares during the period. Finally, Louisiana State Employees Retirement System bought a new position in Halozyme Therapeutics during the fourth quarter worth about $1,371,000. Institutional investors own 97.79% of the company's stock.

Halozyme Therapeutics Price Performance

Shares of NASDAQ HALO traded up $0.83 during mid-day trading on Friday, hitting $38.64. 1,258,837 shares of the stock were exchanged, compared to its average volume of 825,369. The company has a market cap of $4.91 billion, a P/E ratio of 18.31, a PEG ratio of 0.45 and a beta of 1.25. The stock's fifty day simple moving average is $39.56 and its two-hundred day simple moving average is $37.77. The company has a debt-to-equity ratio of 17.89, a quick ratio of 5.50 and a current ratio of 6.64. Halozyme Therapeutics, Inc. has a twelve month low of $29.85 and a twelve month high of $45.00.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings data on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing the consensus estimate of $0.77 by ($0.02). The firm had revenue of $230.04 million for the quarter, compared to analyst estimates of $235.25 million. Halozyme Therapeutics had a return on equity of 248.20% and a net margin of 33.96%. As a group, analysts forecast that Halozyme Therapeutics, Inc. will post 3.45 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have commented on the stock. The Goldman Sachs Group cut their price target on shares of Halozyme Therapeutics from $45.00 to $40.00 and set a "neutral" rating for the company in a research note on Thursday, January 18th. TheStreet cut shares of Halozyme Therapeutics from a "b-" rating to a "c+" rating in a research note on Monday, January 22nd. JMP Securities restated a "market outperform" rating and set a $72.00 price target on shares of Halozyme Therapeutics in a research note on Wednesday, February 21st. Morgan Stanley cut their price target on shares of Halozyme Therapeutics from $61.00 to $59.00 and set an "overweight" rating for the company in a research note on Tuesday, December 26th. Finally, StockNews.com upgraded shares of Halozyme Therapeutics from a "hold" rating to a "buy" rating in a research note on Friday, February 23rd. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat, Halozyme Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $53.29.

Insider Activity at Halozyme Therapeutics

In related news, SVP Michael J. Labarre sold 10,000 shares of the firm's stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $41.64, for a total value of $416,400.00. Following the completion of the sale, the senior vice president now owns 156,558 shares of the company's stock, valued at $6,519,075.12. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders sold a total of 30,000 shares of company stock valued at $1,196,800 over the last quarter. Corporate insiders own 2.40% of the company's stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.